NASDAQ:APTOAptose Biosciences Stock Price, Forecast & News

Aptose Biosciences' stock was trading at $5.84 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, APTO stock has increased by 21.1% and is now trading at $7.07. View which stocks have been most impacted by Coronavirus.

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aptose Biosciences in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Aptose Biosciences.

Aptose Biosciences is scheduled to release its next quarterly earnings announcement on Tuesday, August 4th 2020. View our earnings forecast for Aptose Biosciences.

Aptose Biosciences Inc. (NASDAQ:APTO) released its quarterly earnings results on Tuesday, May, 5th. The biotechnology company reported ($0.15) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.10) by $0.05. View Aptose Biosciences' earnings history.

4 Wall Street analysts have issued twelve-month price objectives for Aptose Biosciences' stock. Their forecasts range from $9.00 to $16.00. On average, they expect Aptose Biosciences' stock price to reach $12.00 in the next year. This suggests a possible upside of 69.7% from the stock's current price. View analysts' price targets for Aptose Biosciences.

Headlines about APTO stock have trended positive this week, InfoTrie reports. The research group identifies positive and negative media coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Aptose Biosciences earned a news sentiment score of 3.0 on InfoTrie's scale. They also assigned media stories about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the stock's share price in the next few days. View the latest news aboutAptose Biosciences.

Aptose Biosciences saw a increase in short interest during the month of May. As of May 15th, there was short interest totaling 991,600 shares, an increase of 59.6% from the April 30th total of 621,300 shares. Based on an average daily volume of 995,400 shares, the short-interest ratio is currently 1.0 days. Currently, 1.4% of the shares of the stock are sold short. View Aptose Biosciences' Current Options Chain.

Some companies that are related to Aptose Biosciences include Alector (ALEC), Fate Therapeutics (FATE), Bill.com (RVMD), Adverum Biotechnologies (ADVM), SpringWorks Therapeutics (SWTX), Sangamo Therapeutics (SGMO), Twist Bioscience (TWST), Mesoblast (MESO), Editas Medicine (EDIT), Adaptimmune Therapeutics (ADAP), Beam Therapeutics (BEAM), I-Mab (BDTX), Regenxbio (RGNX), Coherus Biosciences (CHRS) and Cortexyme (CRTX). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Aptose Biosciences investors own include Aurinia Pharmaceuticals (AUPH), Aurora Cannabis (ACB), NVIDIA (NVDA), Arch Therapeutics (ARTH), Canopy Growth (CGC), Micron Technology (MU), Advanced Micro Devices (AMD), Gilead Sciences (GILD), Anavex Life Sciences (AVXL) and CymaBay Therapeutics (CBAY).

Aptose Biosciences trades on the NASDAQ under the ticker symbol "APTO."

Aptose Biosciences' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Corriente Advisors LLC (3.83%), Pictet Asset Management Ltd. (2.08%), Precept Management LLC (1.02%), Orbimed Advisors LLC (0.74%), P.A.W. Capital Corp (0.79%) and Morgan Stanley (0.53%). Company insiders that own Aptose Biosciences stock include Erich Platzer, Gregory K Chow and William G Rice. View institutional ownership trends for Aptose Biosciences.

APTO stock was sold by a variety of institutional investors in the last quarter, including Orbimed Advisors LLC, Sanders Morris Harris LLC, P.A.W. Capital Corp, Morgan Stanley, Morgan Stanley, and Two Sigma Advisers LP. View insider buying and selling activity for Aptose Biosciences.

APTO stock was purchased by a variety of institutional investors in the last quarter, including Corriente Advisors LLC, Pictet Asset Management Ltd., Precept Management LLC, Atom Investors LP, BNP Paribas Arbitrage SA, Advisor Group Holdings Inc., Patriot Financial Group Insurance Agency LLC, and Raymond James Financial Services Advisors Inc.. Company insiders that have bought Aptose Biosciences stock in the last two years include Gregory K Chow, and William G Rice. View insider buying and selling activity for Aptose Biosciences.

Shares of APTO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of APTO stock can currently be purchased for approximately $7.07.

Aptose Biosciences has a market capitalization of $631.14 million. The biotechnology company earns $-26,280,000.00 in net income (profit) each year or ($0.52) on an earnings per share basis. Aptose Biosciences employs 31 workers across the globe.

The official website for Aptose Biosciences is www.aptose.com.

Aptose Biosciences' mailing address is 12770 HIGH BLUFF DRIVE SUITE 120, SAN DIEGO CA, 92130. The biotechnology company can be reached via phone at 858-926-2730 or via email at [email protected]